Waldmann T A, O'Shea J
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Curr Opin Immunol. 1998 Oct;10(5):507-12. doi: 10.1016/s0952-7915(98)80215-x.
Humanized monoclonal antibodies that recognize the alpha chain of the IL-2 receptor (e.g. daclizumab) have been used to prevent allograft rejection, since this chain is expressed by T cells participating in allograft rejection but not by resting T cells. In a randomized trial, when added to standard cyclosporin-based immunosuppression, daclizumab significantly reduced the frequency of acute rejection of renal transplants.
